This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Nektar Therapeutics Inc (NKTR)

NASDAQ: Health Care

$15.2250 +0.2050 | 1.36%
12/26/14 - 4:00 PM ET
  • Prev Close: 15.02
  • Day's Open: 15.07
  • Volume: 357.84K
  • Avg Vol: 1.26M
  • Shares Outstanding: 128.44M
  • Mkt Cap: 1.93B
  • Div: --
  • Div Yield: --
  • P/E: N/A
  • EPS: -1.40
NKTR Day's Range
$14.95
$15.39
NKTR 52 Week Range
$10.10
$17.53
NKTR Business Summary
Nektar Therapeutics, a clinical-stage biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States.View NKTR key stats
NKTR Performance as of Prev. Close
YTD
32.33%
3-Mo
15.90%
1-Yr
30.84%
3-Yr
175.60%
NKTR EPS Performance
1-Yr Ago
-1.40
2-Yrs Ago
-1.50
3-Yrs Ago
-1.19
NKTR Percentage in these ETFs
0.052%
0.050%
0.030%
0.005%
0.003%
NKTR News

NKTR Nektar Therapeutics Inc

Analysts Ratings for NKTR

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 6 7 7 7
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
GET NKTR ANALYST REPORT

Brokerage Partners

NKTR Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs